CoChat

Revisiting inconsistency in large pharmacogenomic studies

Open access
Safikhani, Zhaleh, Smirnov, Petr, Freeman, Mark, El-Hachem, Nehme, She, Adrian, Rene, Quevedo, Goldenberg, Anna, Birkbak, Nicolai J., Hatzis, Christos, Shi, Leming, Beck, Andrew H., Aerts, Hugo J.W.L., Quackenbush, John, Haibe-Kains, Benjamin · 2017 · F1000Research

Published version of a preprint

Cited by 76

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

In 2013, we published a comparative analysis of mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). While we found good concordance in gene expression profiles, there was substantial inconsistency in the drug responses reported by the GDSC and CCLE projects. We received extensive feedback on the comparisons that we performed. This feedback, along with the release of new data, prompted us to revisit our initial analysis. We present a new analysis using these expanded data, where we address the most significant suggestions for improvements on our published analysis — that targeted therapies and broad cytotoxic drugs should have been treated differently in assessing consistency, that consistency of both molecular profiles and drug sensitivity measurements should be compared across cell lines, and that the software analysis tools provided should have been easier to run, particularly as the GDSC and CCLE released additional data. Our re-analysis supports our previous finding that gene expression data are significantly more consistent than drug sensitivity measurements. Using new statistics to assess data consistency allowed identification of two broad effect drugs and three targeted drugs with moderate to good consistency in drug sensitivity data between GDSC and CCLE. For three other targeted drugs, there were not enough sensitive cell lines to assess the consistency of the pharmacological profiles. We found evidence of inconsistencies in pharmacological phenotypes for the remaining eight drugs. Overall, our findings suggest that the drug sensitivity data in GDSC and CCLE continue to present challenges for robust biomarker discovery. This re-analysis provides additional support for the argument that experimental standardization and validation of pharmacogenomic response will be necessary to advance the broad use of large pharmacogenomic screens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/f1000research.9611.3

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 28

  1. J Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity., Nature., 483, 603-7, 10.1038/nature11003 · DOI · Paper page
  2. S Papillon-Cavanagh, 2013, Comparison and validation of genomic predictors for anticancer drug sensitivity., J Am Med Inform Assoc., 20, 597-602, 10.1136/amiajnl-2012-001442 · DOI · Paper page
  3. Z Dong, 2015, Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection., BMC Cancer., 15, 489, 10.1186/s12885-015-1492-6 · DOI
  4. I Jang, 2014, Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data., Pac Symp Biocomput., 63-74, 10.1142/9789814583220_0007 · DOI · Paper page
  5. I Cortés-Ciriano, 2016, Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel., Bioinformatics., 32, 85-95, 10.1093/bioinformatics/btv529 · DOI · Paper page
  6. C Hatzis, 2014, Enhancing reproducibility in cancer drug screening: how do we move forward?, Cancer Res., 74, 4016-23, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
  7. Z Safikhani, 2016, Assessment of pharmacogenomic agreement [version 1; referees: 3 approved]., F1000 Res., 5, 825, 10.12688/f1000research.8705.1 · DOI
  8. P Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels., Nature., 533, 333-7, 10.1038/nature17987 · DOI · Paper page
  9. P Smirnov, 2016, PharmacoGx: an R package for analysis of large pharmacogenomic datasets., Bioinformatics., 32, 1244-6, 10.1093/bioinformatics/btv723 · DOI · Paper page
  10. H Hong, 2012, Technical reproducibility of genotyping SNP arrays used in genome-wide association studies., PLoS One., 7, e44483, 10.1371/journal.pone.0044483 · DOI
  11. A Goodspeed, 2016, Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics., Mol Cancer Res., 14, 3-13, 10.1158/1541-7786.MCR-15-0189 · DOI · Paper page
  12. W Youden, 1950, Index for rating diagnostic tests., Cancer., 3, 32-5, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
  13. K Pearson, 1895, Note on Regression and Inheritance in the Case of Two Parents., Proc R Soc Lond., 58, 240-2, 10.1098/rspl.1895.0041 · DOI · Paper page
  14. R Somers, 1962, A New Asymmetric Measure of Association for Ordinal Variables., Am Sociol Rev., 27, 799-811, 10.2307/2090408 · DOI · Paper page
  15. A Hudson, 2014, Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery., Cancer Res., 74, 6390-6, 10.1158/0008-5472.CAN-14-1020 · DOI
  16. P Jaccard, 1901, Etude comparative de la distribution florale dans une portion des Alpes et du Jura., 37, 547-579, 10.5169/seals-266450 · doi:10.5169/seals-266450 · Paper page
  17. N Pozdeyev, 2016, Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies., Oncotarget., 7, 51619-51625, 10.18632/oncotarget.10010 · DOI
  18. Z Safikhani, Gene isoforms as expression-based biomarkers predictive of drug response in vitro, 10.1101/160937 · doi:10.1101/160937
  19. A Daemen, 2013, Modeling precision treatment of breast cancer., Genome Biol., 14, R110, 10.1186/gb-2013-14-10-r110 · DOI · Paper page
  20. Z Safikhani, 2016, Safikhani et al. reply., Nature., 540, E2-E4, 10.1038/nature19839 · DOI
  21. P Geeleher, 2016, Consistency in large pharmacogenomic studies., Nature., 540, E1-E2, 10.1038/nature19838 · DOI
  22. R Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data., Biostatistics., 4, 249-64, 10.1093/biostatistics/4.2.249 · DOI · Paper page
  23. W de Leeuw, 2008, Salvaging Affymetrix probes after probe-level re-annotation., BMC Res Notes., 1, 66, 10.1186/1756-0500-1-66 · DOI
  24. S Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer., Nat Biotechnol., 30, 413-21, 10.1038/nbt.2203 · DOI · Paper page
  25. C Wilks, 2014, The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data., Database (Oxford)., 2014, 10.1093/database/bau093 · DOI · Paper page
  26. C Trapnell, 2012, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks., Nat Protoc., 7, 562-78, 10.1038/nprot.2012.016 · DOI · Paper page
  27. A Bairoch, 2015, ExPASy - Cellosaurus [Internet]., Cellosaurus.
  28. Z Safikhani, 2016, Dataset: Revisiting inconsistency in large pharmacogenomics studies., Open Science Framework.

Cited by

See all 76

Metadata

Authors
Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B.
Venue
F1000Research
Published
2017-08-11
Volume
5
Pages
2333
ISSN
2046-1402 (ISSN-L)
OpenAlex
W2953253500
Cited by
76
References
11
FWCI
7.98
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)
Funders
  • Cancer Research Society (19271)
  • National High Technology Research and Development Program of China (2015AA020104)
  • Ontario Institute for Cancer Research
  • National Natural Science Foundation of China (31471239)
  • Canadian Institutes of Health Research
  • The Villum Kann Rasmussen Foundation
  • Princess Margaret Cancer Centre
  • Yale University
  • Canadian Cancer Society Research Institute
  • National Heart, Lung, and Blood Institute (5R01HL111759)
  • NCI GAME-ON Cancer Post-GWAS (5U19 CA148065)
  • Terry Fox Research Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.